

Product datasheet for TL312095V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

Integrin alpha 3 (ITGA3) Human shRNA Lentiviral Particle (Locus ID 3675)

Product data:

Product Type: shRNA Lentiviral Particles

Product Name: Integrin alpha 3 (ITGA3) Human shRNA Lentiviral Particle (Locus ID 3675)

Locus ID: 3675

Synonyms: CD49C; FRP-2; GAP-B3; GAPB3; ILNEB; MSK18; VCA-2; VL3A; VLA3a

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: ITGA3 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 002204, NM 005501, NM 002204.1, NM 002204.2, NM 002204.3, NM 005501.1,

NM 005501.2, BC015344, BC043917, BC136636, BC144328, BC150190, BM978115,

NM 002204.4

UniProt ID: P26006

Summary: The gene encodes a member of the integrin alpha chain family of proteins. Integrins are

heterodimeric integral membrane proteins composed of an alpha chain and a beta chain that function as cell surface adhesion molecules. The encoded preproprotein is proteolytically processed to generate light and heavy chains that comprise the alpha 3 subunit. This subunit joins with a beta 1 subunit to form an integrin that interacts with extracellular matrix proteins including members of the laminin family. Expression of this gene may be correlated with

breast cancer metastasis. [provided by RefSeq, Oct 2015]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).